N-acetyl Semax amidate was characterized as Ac-MEHFPGP-NH2 in a laboratory LC–MS/MS study. The method distinguished the custom-synthesized reference compound from N-acetyl Semax and unmodified Semax. This establishes analytical characterization, not cognitive benefit, human pharmacokinetics or clinical safety.[1]
- The study characterized reference material; it did not test a human treatment or establish the identity or quality of products sold by other suppliers.
- This analytical identification study establishes what was found in the seized/marketed preparations it examined; it is separate from, and does not establish, human clinical effects for either unmodified Semax or N-acetyl Semax amidate.
Inspection history
Clinical review: not reviewed by a qualified clinician.
· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.
· Refetched the original public PDF (same URL, HTTP 200) and reconfirmed the cited Methods/Table 1/Results passages verbatim; no change from the prior inspection. No qualified clinical review.